- Patent covers technology enabling the conversion of intravenous antibody-drug conjugates (ADCs) into subcutaneous formulations using hyaluronidase

- Expected to overcome safety limitations of highly toxic ADCs and drive a paradigm shift in the ADC market

DAEJEON, South Korea, Sept. 26, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that it has filed a PCT (Patent Cooperation Treaty) application for its proprietary technology to develop subcutaneous formulations of ADC therapeutics.

The patent, entitled ‘Use of Subcutaneous Formulations Containing Hyaluronidase in Combination with Antibody-Drug Conjugates, and Methods of Treating Diseases Thereof,’ covers a technology that not only enables the conversion of highly toxic ADC therapeutics into subcutaneous injections using Alteogen's ALT-B4, but also allows control of ADC plasma concentration to improve safety.

The PCT application is an international patent filing system under the Patent Cooperation Treaty that allows applicants to file a single application to simultaneously seek patent protection in multiple countries. By submitting a PCT international application to their national patent office, applicants can obtain the same effect as filing individual patent applications in approximately 150 designated countries.

"For ADC therapeutics, it is crucial to control the administration rate during intravenous delivery to avoid raising plasma concentrations that could cause toxicity issues. By using ALT-B4 to convert intravenous ADCs into subcutaneous injections, administration is faster and more convenient, while pharmacokinetic (PK) results show a gradual increase in plasma ADC levels, which can reduce side effects caused by the toxic compounds conjugated to the ADC," said Soon-Jae Park, CEO of Alteogen.

ALT-B4 is a human recombinant hyaluronidase that enables intravenous infusion formulations of biopharmaceuticals into fast and convenient subcutaneous injections. In November 2024, Alteogen signed a license agreement with Daiichi Sankyo for the subcutaneous formulation conversion of its ADC therapeutic. Daiichi Sankyo is currently developing a subcutaneous version of Enhertu, one of the top-selling ADC drugs, using ALT-B4.

 

About Alteogen

Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ (196170.KQ). For more information, please visit: www.alteogen.com.

Contacts:

Investors & Press
ir@alteogen.com